Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension.

TitleVenous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension.
Publication TypeJournal Article
Year of Publication2019
AuthorsPatsalides A, Oliveira C, Wilcox J, Brown K, Grover K, Gobin YPierre, Dinkin MJ
JournalJ Neurointerv Surg
Volume11
Issue2
Pagination175-178
Date Published2019 Feb
ISSN1759-8486
KeywordsAdolescent, Adult, Body Mass Index, Child, Female, Humans, Intracranial Pressure, Male, Middle Aged, Prospective Studies, Pseudotumor Cerebri, Stents, Transverse Sinuses, Venous Pressure, Young Adult
Abstract

AIMS: We report the cerebrospinal fluid opening pressure (CSF-OP) measurements obtained before and after venous sinus stenting (VSS) in 50 patients with idiopathic intracranial hypertension.

METHODS: The CSF-OP was measured with a spinal tap 3 months before and 3 months after treatment. All data were prospectively collected and included patient demographics, weight (kg), body mass index (BMI), acetazolamide daily dosage (mg), procedural details, complications, venous sinus pressures (mm Hg), trans-stenotic pressure gradient (mm Hg), transverse sinus symmetry, and type of venous sinus stenosis.

RESULTS: The average pretreatment CSF-OP was 37 cm HO (range 25-77) and the average post-treatment CSF-OP was 20.2 cm HO (range 10-36), with an average reduction of 16.8 cm HO (P<0.01). The post-treatment CSF-OP was less than 25 cm HO in 40/50 patients. The average acetazolamide daily dose decreased from 950 mg to 300 mg at the time of 3-month follow-up (P<0.01). No patient required an increase in acetazolamide dose 3 months after VSS. The average weight before treatment was 95.4 kg with an average BMI of 35.41. There was an average increase in body weight of 1.1 kg at the 3-month follow-up with an average increase in BMI of 0.35 (P=0.03).

CONCLUSIONS: We provide evidence that there is a significant decrease in CSF-OP in patients with idiopathic intracranial hypertension 3 months after VSS, independent of acetazolamide usage or weight loss.

DOI10.1136/neurintsurg-2018-014032
Alternate JournalJ Neurointerv Surg
PubMed ID29871989
PubMed Central IDPMC6582809

Weill Cornell Medicine Neurology 525 E. 68th St.
PO Box 117
New York, NY 10065 Phone: (212) 746-6575